- Home
- NSPR vs FATE Comparison
NSPR vs FATE Comparison
Compare NSPR & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- FATE
- Stock Information
- Founded
- NSPR 2005
- FATE 2007
- Country
- NSPR United States
- FATE United States
- Employees
- NSPR N/A
- FATE N/A
- Industry
- NSPR Medical/Dental Instruments
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NSPR Health Care
- FATE Health Care
- Exchange
- NSPR Nasdaq
- FATE Nasdaq
- Market Cap
- NSPR 101.8M
- FATE 116.5M
- IPO Year
- NSPR N/A
- FATE 2013
- Fundamental
- Price
- NSPR $2.41
- FATE $0.95
- Analyst Decision
- NSPR Strong Buy
- FATE Hold
- Analyst Count
- NSPR 2
- FATE 6
- Target Price
- NSPR $4.50
- FATE $3.30
- AVG Volume (30 Days)
- NSPR 78.7K
- FATE 1.4M
- Earning Date
- NSPR 11-11-2025
- FATE 11-11-2025
- Dividend Yield
- NSPR N/A
- FATE N/A
- EPS Growth
- NSPR N/A
- FATE N/A
- EPS
- NSPR N/A
- FATE N/A
- Revenue
- NSPR $7,066,000.00
- FATE $8,470,000.00
- Revenue This Year
- NSPR $7.48
- FATE N/A
- Revenue Next Year
- NSPR $104.39
- FATE N/A
- P/E Ratio
- NSPR N/A
- FATE N/A
- Revenue Growth
- NSPR 7.60
- FATE N/A
- 52 Week Low
- NSPR $1.99
- FATE $0.66
- 52 Week High
- NSPR $3.80
- FATE $4.20
- Technical
- Relative Strength Index (RSI)
- NSPR 47.99
- FATE 39.72
- Support Level
- NSPR $2.37
- FATE $0.94
- Resistance Level
- NSPR $2.45
- FATE $1.08
- Average True Range (ATR)
- NSPR 0.07
- FATE 0.07
- MACD
- NSPR -0.00
- FATE -0.01
- Stochastic Oscillator
- NSPR 37.50
- FATE 9.00
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.